A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis
- PMID: 26105574
- DOI: 10.3111/13696998.2015.1064934
A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis
Abstract
Objective: Procalcitonin (PCT) is a specific marker for differentiating bacterial from non-infective causes of inflammation. It can be used to guide initiation and duration of antibiotic therapy in intensive care unit (ICU) patients with suspected sepsis, and might reduce the duration of hospital stay. Limiting antibiotic treatment duration is highly important because antibiotic over-use may cause patient harm, prolonged hospital stay, and resistance development. Several systematic reviews show that a PCT algorithm for antibiotic discontinuation is safe, but upfront investment required for PCT remains an important barrier against implementation. The current study investigates to what extent this PCT algorithm is a cost-effective use of scarce healthcare resources in ICU patients with sepsis compared to current practice.
Methods: A decision tree was developed to estimate the health economic consequences of the PCT algorithm for antibiotic discontinuation from a Dutch hospital perspective. Input data were obtained from a systematic literature review. When necessary, additional information was gathered from open interviews with clinical chemists and intensivists. The primary effectiveness measure is defined as the number of antibiotic days, and cost-effectiveness is expressed as incremental costs per antibiotic day avoided.
Results: The PCT algorithm for antibiotic discontinuation is expected to reduce hospital spending by circa € 3503 per patient, indicating savings of 9.2%. Savings are mainly due to reductions in length of hospital stay, number of blood cultures performed, and, importantly, days on antibiotic therapy. Probabilistic and one-way sensitivity analyses showed the model outcome to be robust against changes in model inputs.
Conclusion: Proven safe, a PCT algorithm for antibiotic discontinuation is a cost-effective means of reducing antibiotic exposure in adult ICU patients with sepsis, compared to current practice. Additional resources required for PCT are more than offset by downstream cost savings. This finding is highly important given the aim of preventing widespread antibiotic resistance.
Keywords: Antibiotics; Cost-effectiveness; Intensive care; Procalcitonin; Sepsis.
Similar articles
-
Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands.Crit Care. 2018 Nov 13;22(1):293. doi: 10.1186/s13054-018-2234-3. Crit Care. 2018. PMID: 30424796 Free PMC article. Clinical Trial.
-
Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.Health Technol Assess. 2015 Nov;19(96):v-xxv, 1-236. doi: 10.3310/hta19960. Health Technol Assess. 2015. PMID: 26569153 Free PMC article. Review.
-
The use of a standardized PCT-algorithm reduces costs in intensive care in septic patients - a DRG-based simulation model.Eur J Med Res. 2011 Dec 2;16(12):543-8. doi: 10.1186/2047-783x-16-12-543. Eur J Med Res. 2011. PMID: 22112361 Free PMC article.
-
Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis?Infect Control Hosp Epidemiol. 2015 Mar;36(3):265-72. doi: 10.1017/ice.2014.60. Infect Control Hosp Epidemiol. 2015. PMID: 25695167
-
Procalcitonin to guide antibiotic therapy in the ICU.Int J Antimicrob Agents. 2015 Dec;46 Suppl 1:S19-24. doi: 10.1016/j.ijantimicag.2015.10.012. Epub 2015 Nov 1. Int J Antimicrob Agents. 2015. PMID: 26607343 Review.
Cited by
-
Severe Acute Bronchial Asthma with Sepsis: Determining the Status of Biomarkers in the Diagnosis of the Disease.Diagnostics (Basel). 2023 Aug 16;13(16):2691. doi: 10.3390/diagnostics13162691. Diagnostics (Basel). 2023. PMID: 37627950 Free PMC article. Review.
-
Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis.BMC Infect Dis. 2017 Jul 24;17(1):514. doi: 10.1186/s12879-017-2622-3. BMC Infect Dis. 2017. PMID: 28738787 Free PMC article.
-
Checking procalcitonin suitability for prognosis and antimicrobial therapy monitoring in burn patients.Burns Trauma. 2018 Mar 31;6:10. doi: 10.1186/s41038-018-0112-5. eCollection 2018. Burns Trauma. 2018. PMID: 29610766 Free PMC article.
-
Understanding how diagnostics influence antimicrobial decision-making is key to successful clinical trial design.Clin Microbiol Infect. 2023 Jun;29(6):666-669. doi: 10.1016/j.cmi.2023.03.010. Epub 2023 Mar 12. Clin Microbiol Infect. 2023. PMID: 36918143 Free PMC article. No abstract available.
-
Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands.Crit Care. 2018 Nov 13;22(1):293. doi: 10.1186/s13054-018-2234-3. Crit Care. 2018. PMID: 30424796 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical